Please assess the completion status of the following clinical trial:

Trial Title: Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer~* Women should have received no prior therapy for their disease~* Women who are planning to undergo hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy for the management of their endometrial cancer~* Women must have the ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Women who are receiving any other investigational agents~* Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this study~* Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides~* Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Women with a history of prior loop electrosurgical excision procedure (LEEP) or cone procedures performed on their cervix~* Women with a history of lymphedema, lymphoma, or lymphatic hyperplasia (Castleman disease)~* Women with a history of a prior malignancy~* Women may also be excluded at the discretion of their surgeon if he or she feels that the patient is not an appropriate candidate

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (SLN mapping, biopsy, surgery) (Type: EXPERIMENTAL): Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).